Welcome to our dedicated page for Lifevantage news (Ticker: LFVN), a resource for investors and traders seeking the latest updates and insights on Lifevantage stock.
LifeVantage Corporation (Nasdaq: LFVN) is a health and wellness company centered on nutrigenomics and cellular activation, and its news flow reflects this focus. The company regularly issues updates on its activator-based product portfolio, consultant community, scientific research, and participation in investor and industry events. As the Activation company, LifeVantage highlights how its products, such as the Protandim family, TrueScience Liquid Collagen, the MindBody GLP-1 System, and the comprehensive gut activator P84, fit into broader wellness systems and scientific narratives.
News about LifeVantage often covers new product launches and enhancements, including additions to its activation-supporting nutrients, AXIO nootropic energy drink mixes, and TrueScience skin and hair care line. Company communications also describe major field events like Momentum Academy and Global Kickoff, where Consultants receive training, hear about new tools, and learn strategies related to enrollment, retention, and advancement. These events frequently coincide with the introduction of new offerings or the integration of acquired product lines such as LoveBiome’s P84.
Investors following LFVN can also expect announcements on quarterly and annual financial results, dividend declarations, share repurchase activity, and guidance ranges, as well as notices of participation in conferences and fireside chats. The company’s releases include commentary from management on strategic initiatives such as integrating LoveBiome assets, expanding its wellness ecosystem, and advancing digital capabilities like the Daily Activation app.
This news page aggregates these updates so readers can track developments in LifeVantage’s product science, consultant network, and corporate strategy in one place. For anyone monitoring LFVN stock, the consultant-driven business model, or trends in nutrigenomics-focused wellness products, the news feed provides an ongoing view of how the company communicates its progress and priorities.
LifeVantage Corporation (Nasdaq: LFVN) announced a five-year donation commitment to the Linus Pauling Institute (LPI) at Oregon State University, contributing to the LPI Research Innovation Fund. This partnership aims to enhance health through nutrition research. Senior VP Dr. Brian Dixon will join LPI's Director’s Circle, providing strategic insight. The collaboration allows LifeVantage to access third-party research and engage with leading researchers, aligning both organizations' goals of optimizing health through innovative nutrition.
LifeVantage Corporation (Nasdaq: LFVN) announced its fourth quarter and full year financial results for fiscal 2021, reporting revenue of $220.2 million, a 5.5% decline from the previous year. The fourth quarter revenue reached $54.8 million, down 7.7% year-over-year but up 6.2% sequentially. Adjusted EPS for Q4 was $0.31, up 10.7%. The company repurchased 1.2 million shares for $11.9 million and has a solid balance sheet with $23.2 million in cash and no debt. Guidance for fiscal 2022 forecasts revenue between $225 million and $235 million.
LifeVantage Corporation (Nasdaq: LFVN) is set to announce its financial results for Q4 and full fiscal year ending June 30, 2021, on August 19, 2021, after market close. A conference call with investors will follow at 2:30 p.m. MT. Interested parties can join by calling (877) 705-6003 for U.S. participants or (201) 493-6725 internationally. A replay of the call will be available until August 26, 2021. The company specializes in nutrigenomics and offers a range of health products, including dietary supplements and skincare lines.
LifeVantage Corporation (LFVN) reported Q3 fiscal 2021 results with revenue of $51.6 million, an 8.0% decline year-over-year and a 12.6% sequential drop. Active accounts decreased by 4.0% from last year. Notably, adjusted EPS rose by 53.8% to $0.20 despite challenges from COVID-19 supply chain disruptions. Gross profit decreased 8.8% to $42.8 million, and adjusted EBITDA fell 5.7% to $4.8 million. The company maintains a strong balance sheet with $19.0 million in cash and no debt, while updating its fiscal 2021 revenue guidance to $220-$223 million.
LifeVantage Corporation (Nasdaq: LFVN) will disclose its Q3 financial results for the period ending March 31, 2021, on April 29, 2021. Following the release, a conference call is scheduled for 2:30 p.m. MT (4:30 p.m. ET) to discuss the results. Interested investors can join via phone or listen to a live webcast on the company's website. A replay of the call will be available until May 6, 2021. LifeVantage specializes in Nutrigenomics, focusing on dietary supplements and skincare products, including its Protandim® line.
LifeVantage Corporation (Nasdaq: LFVN) will disclose its financial results for Q2 ending December 31, 2020, on February 2, 2021, after market closure. A conference call will occur at 2:30 PM MT (4:30 PM ET) that day for investors. Participants can join by calling (877) 705-6003 or (201) 493-6725 for international access. A replay will be available post-call until February 9, 2021. LifeVantage specializes in Nutrigenomics and offers various nutraceuticals and personal care products, including Protandim® and TrueScience®.
LifeVantage Corporation (Nasdaq: LFVN) reported its first quarter fiscal 2021 results, achieving adjusted EPS of $0.25, up 92.3% year-over-year. Total revenue reached $54.8 million, a 2.5% decline from the previous year, primarily due to the absence of an Elite Academy event. Active accounts decreased by 3.9% sequentially. Gross profit was $45.4 million, 82.9% of revenue. Adjusted EBITDA increased by 42.5% to $6.7 million. The company maintains a strong balance sheet with $18 million in cash and no debt. Guidance for fiscal 2021 remains unchanged, projecting revenue of $240-$251 million.
LifeVantage Corporation (Nasdaq: LFVN) will announce its financial results for the first quarter ended September 30, 2020, on November 3, 2020, after market close. A conference call for investors is scheduled for 2:30 p.m. MT. Interested participants can join by calling (877) 705-6003, with a replay available until November 10. The event will also be webcast live on the company's website. LifeVantage specializes in Nutrigenomics, offering a variety of nutraceutical supplements and skin care products, including its popular Protandim® line.
LifeVantage Corporation (Nasdaq: LFVN) announced the resignation of CEO Darren Jensen on September 3, 2020, with Chief Financial Officer Steven Fife appointed as the interim CEO. The Board is seeking a permanent successor. The company's sales and marketing teams will merge, led by Chief Sales Officer Justin Rose. LifeVantage reaffirmed its fiscal 2021 guidance, expecting revenue of $240 million to $251 million, adjusted EBITDA of $25 million to $27 million, and adjusted earnings per share between $0.87 and $0.91, while noting potential impacts from the evolving COVID-19 pandemic.
LifeVantage Corporation (Nasdaq: LFVN) announced that CEO Darren Jensen and CFO Steve Fife will participate in two upcoming virtual investor conferences. The LD Micro 500 conference is scheduled for September 1-4, with a presentation on September 2 at 9:20 a.m. MT. They will also attend the H.C. Wainwright 22nd Annual Global Investment Conference from September 14-16, presenting on September 15. Both presentations will be available via webcast on the company’s investor relations website.
FAQ
What is the current stock price of Lifevantage (LFVN)?
What is the market cap of Lifevantage (LFVN)?
